Jay T Bishoff1, Stephen J Freedland2, Leah Gerber2, Pierre Tennstedt2, Julia Reid2, William Welbourn2, Markus Graefen2, Zaina Sangale2, Eliso Tikishvili2, Jimmy Park2, Adib Younus2, Alexander Gutin2, Jerry S Lanchbury2, Guido Sauter2, Michael Brawer2, Steven Stone2, Thorsten Schlomm2. 1. Intermountain Healthcare (JTB), Salt Lake City, Utah; Myriad Genetics, Inc. (JR, WW, ZS, ET, JP, AY, AG, JSL, MB), Salt Lake City, Utah; Department of Surgery, Durham Veterans Affairs Medical Center (SJF, LG), Durham, North Carolina; Department of Surgery (Urology) (SJF, LG), Duke University School of Medicine, Durham, North Carolina; Department of Pathology (SJF), Duke University School of Medicine, Durham, North Carolina; Martini-Clinic, Prostate Cancer Center (PT, MG), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute for Pathology (GS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: Jay.Bishoff@imail.org. 2. Intermountain Healthcare (JTB), Salt Lake City, Utah; Myriad Genetics, Inc. (JR, WW, ZS, ET, JP, AY, AG, JSL, MB), Salt Lake City, Utah; Department of Surgery, Durham Veterans Affairs Medical Center (SJF, LG), Durham, North Carolina; Department of Surgery (Urology) (SJF, LG), Duke University School of Medicine, Durham, North Carolina; Department of Pathology (SJF), Duke University School of Medicine, Durham, North Carolina; Martini-Clinic, Prostate Cancer Center (PT, MG), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute for Pathology (GS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy. MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease. RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p=2.4×10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p=4.7×10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p=2.1×10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p=8.2×10(-6)). CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.
PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy. MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease. RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p=2.4×10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p=4.7×10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p=2.1×10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p=8.2×10(-6)). CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.
Authors: Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2015-10-19 Impact factor: 4.104
Authors: Rohina Rubicz; Shanshan Zhao; Craig April; Jonathan L Wright; Suzanne Kolb; Ilsa Coleman; Daniel W Lin; Peter S Nelson; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford Journal: Prostate Date: 2015-05-18 Impact factor: 4.104
Authors: Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer Journal: Am Soc Clin Oncol Educ Book Date: 2016